Articles / Hyperparathyroidism – more than just stones, bones and groans
0 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
These are activities that require reflection on feedback about your work.
These are activities that use your work data to ensure quality results.
No longer is it okay to just monitor a patient with mild hyperparathyroidism as research shows the untreated condition is associated with a significantly increased risk of cardiovascular death.
Speaking on a recent Healthed podcast, endocrine surgeon Professor Leigh Delbridge said historically it was thought mild primary hyperparathyroidism caused the well-recognised ‘stones, bones and groans’ symptoms but there were no long-term problems.
However, over the last decade, research has showed that untreated mild primary hyperparathyroidism can significantly affect the cardiovascular system, in particular it is associated with a 2.2 times increased risk of dying of a cardiovascular event.
Managing Paediatric Anxiety in General Practice
Non-Hormonal & Hormonal Options for Hot Flushes
Why is LDL Control Important?
Muscle Health in Chronic Disease: A Practical Guide for GPs
Modified but kept in place
Eliminated entirely without replacement
Maintained as is
Completely replaced with an alternative system
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease